Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157641. PMID:36895850. IF:4.300(Q2/3D).

Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).

Hwang, TJ, Trinh, QD, Tibau, A, Vokinger, KN. Reforms to accelerated approval of new medicines: long overdue. LANCET. 2022; 400(10349)DOI:10.1016/S0140-6736(22)01276-4. PMID:35835129. IF:168.900(Q1/1D).

Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Rey, PM, Zielinski, H, Villacampa, F, Bigot, P, Zoltan, B, Parikh, O, Alba, DV, Jellvert, D, Flasko, T, Gallardo, E, Caparros, MJR, Purkalne, G, Suenaert, P, Karlsson-Parra, A, Ljungberg, B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2.500(Q3/6D).

Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).

Molto C., Tibau A., Bujosa A., Tapia J.C., Mittal A., Tamimi F., Amir E.. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:(Q/D).

Isla D., Majem M.. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12)DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8.000(Q1/2D).

Argilés G., Valladares-Ayerbes M., Viéitez J.M., García-Paredes B., Rodríguez-Garrote M., Rivera F., Goldberg R.M., Ciardiello F., Tabernero J.M., Goldberg R., Argilés, Tabernero J., Mulet N., Limón M.L., Valladares M., Jiménez P., Vieitez J.M., Grávalos C., García-Alfonso P., Santos C., Páez D., Tobeña M., Sastre J., García Paredes B., Benavides M., Aranda E., Cano M.T., Loupakis F., Rguez Garrote M., Guillén C., Rivera M.F., Safont J., Hiret S., Bennouna J., Pannier D., Malka D., Falcone A., Cremolini C., The. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8.400(Q1/2D).

Martin-Broto J., Redondo A., Moura D.S., Valverde C., Morales J.M., Lopez-Pousa A., Martinez-Trufero J., Gutierrez A., Díaz-Beveridge R., Luna P., Martinez-Marin V., Marcilla D., Arribas I., Ledesma P., Lopez-Martin J.A., Di Lernia D., Zamora J., Hindi N.. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022; 13(1)DOI:10.1038/s41467-022-33975-6. PMID:36271011. IF:16.600(Q1/1D).

Blay J.Y., Palmerini E., Bollard J., Aguiar S., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Chs C.-S., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden, 5th, Chacón M., Clara-Altamirano M.A., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., Dei Tos A.P., Dominguez Malagon H.R., Donati D.M., Dufresne A., Eriksson M., Farias-Loza M., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gerderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Hindi N., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes A., Lopes David B.B., Lopez-Pousa A., Lutter G., Maki R.G., Martinez-Said H., Martinez-Tlahuel J.L., Mello C.A., Morales Pérez J.M., Moura D.S., Nakagawa S.A., Nascimento A.G., Ortiz-Cruz E.J., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Santos T.G., Scotlandi K., Mlg S., Soulé T., Stacchiotti S., Valverde C.M., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 180DOI:10.1016/j.critrevonc.2022.103827. PMID:36220678. IF:6.200(Q1/3D).

Salvador Bofill J., Moreno Anton F., Rodriguez Sanchez C.A., Galve Calvo E., Hernando Melia C., Ciruelos Gil E.M., Vidal M., Jiménez-Rodriguez B., De la Cruz Merino L., Martínez Jañez N., Villanueva Vazquez R., de Toro Salas R., Anton Torres A., Alvarez Lopez I.M., Gavila Gregori J., Quiroga Garcia V., Vicente Rubio E., De la Haba-Rodriguez J., Gonzalez-Santiago S., Diaz Fernandez N., Barnadas Molins A., Cantos Sanchez de Ibargüen B., Delgado Mingorance J.I., Bellet Ezquerra M., de Casa S., Gimeno A., Martin M.. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. BREAST. 2022; 66DOI:10.1016/j.breast.2022.09.006. PMID:36206609. IF:3.900(Q1/3D).

Pena-Couso L., Ercibengoa M., Mercadillo F., Gómez-Sánchez D., Inglada-Pérez L., Santos M., Lanillos J., Gutiérrez-Abad D., Hernández A., Carbonell P., Letón R., Robledo M., Rodríguez-Antona C., Perea J., Urioste M., Alonso M.Á., Andrés R., Arévalo S., del Mar Arias M., Balmaña J., Beristain E., Blanco I., Boronat M., Brunet J., Cózar M.V., del Campo M., Díaz A., Gabau E., Barcina M.J., González M., Guitart M., Hernán I., Hernández H.S., Hernando S., Lacambra C., Lasa A., Lastra E., Llort G., del Rosario Marín M., Marrupe D., Martínez F., Martínez V., Martorell L., Orera M., Pedrinaci S., Pérez P., Pineda M., Plasencia A.M., Cajal T.R., Robles L., Rodà D., Rodríguez N., Rosell J., Sáez R., Salvat M., Sánchez A., Santana A., Soto J.L., Toll A., Tuneu A., Vázquez C.. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients. Orphanet Journal of Rare Diseases. 2022; 17(1)DOI:10.1186/s13023-021-02079-7. PMID:35227301. IF:3.700(Q2/4D).

Hidalgo-Ríos S., Carrillo-García J., Moura D.S., Stacchiotti S., López-Pousa A., Redondo A., Italiano A., Gutiérrez A., Grignani G., Hindi N., López-Guerrero J.-A., Muro X.G.D., Trufero J.M., Palmerini E., García A.S., Bernabeu D., Le Cesne A., Casali P.G., Blay J.-Y., Cruz Jurado J., Martin-Broto J.. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib. Cancers. 2022; 14(17)DOI:10.3390/cancers14174186. PMID:36077723. IF:5.200(Q2/3D).

Bellmunt J., Valderrama B.P., Puente J., Grande E., Bolós M.V., Lainez N., Vázquez S., Maroto P., Climent M.Á., Garcia del Muro X., Arranz J.Á., Durán I.. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103683. PMID:35439541. IF:6.200(Q1/3D).

Aguado-Flor E., Fuentes-Raspall M.J., Gonzalo R., Alonso C., Ramón y Cajal T., Fisas D., Seoane A., Sánchez-Pla Á., Giralt J., Díez O., Gutiérrez-Enríquez S.. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.825703. PMID:35686103. IF:4.700(Q2/4D).

Provencio M., Serna-Blasco R., Nadal E., Insa A., García-Campelo M.R., Casal Rubio J., Dómine M., Majem M., Rodríguez-Abreu D., Martínez-Martí A., De Castro Carpeño J., Cobo M., López Vivanco G., Del Barco E., Bernabé Caro R., Viñolas N., Barneto Aranda I., Viteri S., Pereira E., Royuela A., Calvo V., Martín-López J., García-García F., Casarrubios M., Franco F., Sánchez-Herrero E., Massuti B., Cruz-Bermúdez A., Romero A.. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). JOURNAL OF CLINICAL ONCOLOGY. 2022; 71DOI:10.1200/JCO.21.02660. PMID:35576508. IF:45.300(Q1/1D).

Riudavets M., Auclin E., Mosteiro M., Dempsey N., Majem M., Lobefaro R., López-Castro R., Bosch-Barrera J., Pilotto S., Escalera E., Tagliamento M., Mosquera J., Zalcman G., Aboubakar-Nana F., Ponce S., Dal Maso A., Spotti M., Mielgo-Rubio X., Mussat E., Reyes R., Benítez J.-C., Lupinacci L., Duchemann B., De Giglio A., Blaquier J., Audigier-Valette C., Scheffler M., Nadal E., Lopes G., Signorelli D., Garcia-Campelo R., Menis J., Bluthgen V., Campayo M., Recondo G., Besse B., Planchard D., Mezquita L.. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8.400(Q1/2D).

Bernabé-Caro R., Garrido P., García-Campelo R., Palmero R., Artal Á., Bayona C., Rodríguez-Abreu D., López-Brea M., Paredes A., Vicente D., Torres J.M.S., Majem M., Diz P., Gordo R., Coca M., de Castro J.. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1)DOI:10.18632/oncotarget.28244. PMID:. IF:(Q/D).

Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Álava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., EURACAN and GENTURIS. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.005. PMID:34560242. IF:50.500(Q1/1D).

Peters S., Pujol J.-L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A., Molinier O., Nackaerts K., Insa Mollá A., Gervais R., López Vivanco G., Madelaine J., Mazieres J., Faehling M., Griesinger F., Majem M., González Larriba J.L., Provencio Pulla M., Vervita K., Roschitzki-Voser H., Ruepp B., Mitchell P., Stahel R.A., Le Pechoux C., De Ruysscher D., Stahel R., Hiltbrunner A., Pardo-Contreras M., Gasca-Ruchti A., Giacomelli N., Kammler R., Marti N., Pfister R., Piguet A.C., Roux S., Troesch S., Schneider M., Schweri R., Zigomo I., Tsourti Z., Zygoura P., Tsouprou S., Kassapian M., Dimopoulou G., Andriakopoulou C., Morin F., Amour E., Mariaule G., Archirel N., Fernandez M., Pereira E., Benito L., Lopez K., Hernández A., Chinchen S., Jurkovic H., Livingstone A., Mitchell J., Walker M., Ng S., Steer C., Briscoe K., Saqib A., Abdi E., Houghton B., O'Byrne K., Chittajallu B.R., Hughes B.G., Black A., Werner H., Zalcman G., Vaylet F., Merle P., Monnet I., Girard N., Souquet P.-J., Barlesi F., Debieuvre D., Senellart H., Poudenx M., Dixmier A., Pouessel D., Cadranel J., Lena H., Quoix E., Friard S., Audigier-Valette C., Pichon E., Kokowski K., Kirchen H., Tufman A., De-Colle C., de Langen J., Insa A., Massutí B., Pulla M.P., Aix S.P., Villanueva N., Vivanco G.L., Franks K., Califano R.. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50.500(Q1/1D).

Riudavets, M, Bosch-Barrera, J, Cabezon-Gutierrez, L, Tain, PD, Hernandez, A, Alonso, M, Blanco, R, Galvez, E, Insa, A, Mielgo, X, Moran, T, Ponce, S, Roa, D, Sanchez, JM, Majem, M. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical & Translational Oncology. 2021; 23(12)DOI:10.1007/s12094-021-02661-2. PMID:34292495. IF:3.340(Q3/7D).

Martinez-Trufero, J, Jurado, JC, Gomez-Mateo, MC, Bernabeu, D, Floria, LJ, Lavernia, J, Sebio, A, del Muro, XG, Alvarez, R, Correa, R, Hernandez-Leon, CN, Marquina, G, Hindi, N, Redondo, A, Martinez, V, Asencio, JM, Mata, C, Morales, CMV, Martin-Broto, J. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102259. PMID:34311246. IF:13.608(Q1/1D).

Martinez-Trufero, J, Jurado, JC, Hernandez-Leon, CN, Correa, R, Asencio, JM, Bernabeu, D, Alvarez, R, Hindi, N, Mata, C, Marquina, G, Martinez, V, Redondo, A, Floria, LJ, Gomez-Mateo, MC, Lavernia, J, Sebio, A, del Muro, XG, Martin-Broto, J, Valverde-Morales, C. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102260. PMID:34340159. IF:13.608(Q1/1D).

Puente, J, Pinto, A, Mendez-Vidal, MJ, del Muro, XG, Maroto, P, Vazquez, S, Luque-Caro, R, Anido, U, Strunz-McKendry, T, Upadhyay, A, Montes, J, Nuñez, AO, Portela, JG, Castellano, D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2025; 27(5)DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2.500(Q3/6D).

Palmerini, E, Pousa, AL, Grignani, G, Redondo, A, Hindi, N, Provenzano, S, Sebio, A, Martin, JAL, Valverde, C, Trufero, JM, Gutierrez, A, de Alava, E, Gomez, MPA, D'Ambrosio, L, Collini, P, Bazzocchi, A, Moura, DS, Ibrahim, T, Stacchiotti, S, Broto, JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2025; 131(1)DOI:10.1002/cncr.35628. PMID:39540661. IF:5.100(Q1/3D).

Salazar, J, Arranz, MJ, Martin-Broto, J, Bautista, F, Martínez-García, J, Martínez-Trufero, J, Vidal-Insua, Y, Echebarria-Barona, A, Díaz-Beveridge, R, Valverde, C, Luna, P, Vaz-Salgado, MA, Blay, P, Alvarez, R, Sebio, A. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024; 16(12)DOI:10.3390/pharmaceutics16121585. PMID:39771563. IF:5.500(Q1/1D).

Caballero-Borrego, M, Piedra, A, Gallego, O, López-Pousa, A, Castillo, P, Navarrete, P, Prat, A, Grau, JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology. 2024; 90(6)DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1.800(Q2/4D).

Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).

Provencio, M, Nadal, E, Insa, A, Campelo, RG, Casal, J, Dómine, M, Massuti, B, Majem, M, Rodríguez-Abreu, D, Martínez-Marti, A, de Castro, J, de Antonio, DG, Macia, I, Figueroa, S, Vago, LF, Calvo, V, Palmero, R, Sierra-Rodero, B, Martínez-Toledo, C, Molina-Alejandre, M, Serna-Blasco, R, Romero, A, Cruz-Bermúdez, A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11)DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:35.900(Q1/1D).

Borque-Fernando, A, Zapatero, A, Manneh, R, Alonso-Gordoa, T, Couñago, F, Domínguez-Esteban, M, López-Valcárcel, M, Rodríguez-Antolín, A, Sala-González, N, Sanmamed, N, Maroto, P. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. Actas Urologicas Espanolas. 2024; 48(9)DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1.200(Q3/7D).

Gray, JE, Markovets, A, Reungwetwattana, T, Majem, M, Nogami, N, Peled, N, Lee, JS, Cho, BC, Chewaskulyong, B, John, T, Han, JY, Sebastian, M, Todd, A, Rukazenkov, Y, Barrett, C, Chmielecki, J, Lee, SM, Ramalingam, SS, Hartmaier, R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11)DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:20.800(Q1/1D).

Mirallas, O, Martin-Cullell, B, Navarro, V, Vega, KS, Recuero-Borau, J, Gómez-Puerto, D, López-Valbuena, D, de Torres, CS, Andurell, L, Pedrola, A, Berché, R, Palmas, F, Ucha, JM, Villacampa, G, Rezqallah, A, Sanz-Beltran, J, Bach, R, Bueno, S, Viaplana, C, Molina, G, Hernando-Calvo, A, Aguilar-Company, J, Roca, M, Muñoz-Couselo, E, Martínez-Martí, A, Alonso, A, Eremiev, S, Macarulla, T, Oaknin, A, Saura, C, Élez, E, Felip, E, Peñuelas, A, Burgos, R, Pardo, PG, Garralda, E, Tabernero, J, Serradell, S, Servitja, S, Paez, D, Dienstmann, R, Carles, J. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study. Lancet Regional Health-Europe. 2024; 46DOI:10.1016/j.lanepe.2024.101063. PMID:39529819. IF:13.000(Q1/1D).

Mazariegos, M, Girones, R, Del Barco, S, Garcia, A, Velilla, G, Hernandez, A, Alonso, M, Ferreira, L, Luque, N, Fernández,, Quintanar, T, Peralta, S, Ceballos,, Iza, E, Sanchez, M, Martín, EP, Casado, EA, Mazarico, J, Duran, G, Alvarez, P, Ayala, P, Gallego, O, Sarabia, R, de las Penas, R, Nuñez,, Morilla,, Cunquero, A, Cheverria, N, Moya,, Vaz, M, Luque, R, Esteve, A, Pineda, E. P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY. NEURO-ONCOLOGY. 2024; 26DOI:10.1093/neuonc/noae144.446. PMID:. IF:13.400(Q1/1D).

Vidal, N, Climent, MA, Pérez, S, Méndez-Vidal, MJ, Anguera, G, Salas, IM, Gallardo, E, Cuéllar-Rivas, MA, Molina-Cerrillo, J, Martín, A, Rodriguez-Vida, A, Casado, EA, Gonzalez, M, Domènech, M, Kareaga, MM, Calvo, OF, Guzmán, JCV, Estévez, SV, Gonzàlez-del-Alba, A, Puente, J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03744-6. PMID:39369361. IF:2.500(Q3/6D).

Bellmunt, J, Maroto, P, Bonfill, T, Vazquez, F, Perez-Gracia, JL, Juanpere, N, Hernandez-Prat, A, Hernandez-Llodra, S, Rovira, A, Juan, OS, Rodriguez-Vida, A. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clinical Genitourinary Cancer. 2024; 22(5)DOI:10.1016/j.clgc.2024.102123. PMID:38905731. IF:2.700(Q2/3D).

Abu Remilah, A, Krayim, B, Amir, E, Tibau, A, Robson, ME, Abuhadra, N, Chen, Y, Shepshelovich, D, Goldvaser, H. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2024; 202DOI:10.1016/j.critrevonc.2024.104455. PMID:39067779. IF:5.600(Q1/2D).

Waterhouse, DM, Rothschild, S, Dooms, C, Mennecier, B, Bozorgmehr, F, Majem, M, Heuvel, MHV, Linardou, H, Cho, BC, Roberts-Thomson, R, Tanaka, K, Blais, N, Schvartsman, G, Hansen, KH, Chmielewska, I, Forster, MD, Giannopoulou, C, Stollenwerk, B, Obiozor, CC, Wang, Y, Novello, S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. LUNG CANCER. 2024; 196DOI:10.1016/j.lungcan.2024.107921. PMID:39303400. IF:4.400(Q1/2D).

de Castro, J, Dols, MC, Gómez, MD, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Campelo, RG. Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Jones, DR, Wakelee, H, Spicer, JD, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Wang, W, Chen, H, Dooms, C, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Huang, HC, Novello, S, Jensen, E, Keller, SM, Samkari, A, Kalhor, N. Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, Sullivan, IG, Torrego, A, Surrallés, J, Purdy, J, Carmona, MA, Dunsford, H, Wubs, M. An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).